Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase increases glycolysis, hypertrophy, and myocyte resistance to hypoxia

Qianwen Wang,1,6 Rajakumar V. Donthi,2,6 Jianxun Wang,3 Alex J. Lange,4 Lewis J. Watson,1,5 Steven P. Jones,1,5 and Paul N. Epstein2

Departments of 1Physiology, 2Department of Pediatrics-Diabetes Research, and 3Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky; 4Department of Biochemistry, Molecular Biology, and Biophysics, Medical School, University of Minnesota, Minneapolis, Minnesota; and 5Institute of Molecular Cardiology, University of Louisville School of Medicine, Louisville, Kentucky

Submitted 20 December 2007; accepted in final form 28 April 2008

Wang Q, Donthi RV, Wang J, Lange AJ, Watson LJ, Jones SP, Epstein PN. Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase increases glycolysis, hypertrophy, and myocyte resistance to hypoxia. Am J Physiol Heart Circ Physiol 294: H2889–H2897, 2008. First published May 2, 2008; doi:10.1152/ajpheart.91501.2007.—During ischemia and heart failure, there is an increase in cardiac glycolysis. To understand if this is beneficial or detrimental to the heart, we chronically elevated glycolysis by cardiac-specific overexpression of phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2) in transgenic mice. PFK-2 controls the level of fructose-2,6-bisphosphate (Fru-2,6-P2), an important regulator of phosphofructokinase and glycolysis. Transgenic mice had over a threefold elevation in levels of Fru-2,6-P2. Cardiac metabolites upstream of phosphofructokinase were significantly reduced, as would be expected by the activation of phosphofructokinase. In perfused hearts, the transgene caused a significant increase in glycolysis that was less sensitive to inhibition by palmitate. Conversely, oxidation of palmitate was reduced by close to 50%. The elevation in glycolysis made isolated cardiomyocytes resistant to contractile inhibition by hypoxia, but in vivo the transgene had no effect on ischemia-reperfusion injury. Transgenic hearts exhibited pathology: the heart weight-to-body weight ratio was increased 17%, cardiomyocyte length was greater, and cardiac fibrosis was increased. However, the transgene did not change insulin sensitivity. These results show that the elevation in glycolysis provides acute benefits against hypoxia, but the chronic increase in glycolysis or reduction in fatty acid oxidation interferes with normal cardiac metabolism, which may be detrimental to the heart.

IN A HEALTHY HEART, glucose accounts for a small percentage of the energy supply, but glucose comes to play a more important role in cardiac pathology. Glycolysis increases in congestive heart failure (CHF) and cardiac hypertrophy (7). Glycolysis also rises during cardiac ischemia (28). In acute ischemia, glycolysis can become the only source of ATP and is therefore needed for the survival of cardiomyocytes. However, chronically elevated glycolysis, as occurs during long-term CHF, may not be so beneficial. Rather than being an adaptive response to heart failure, the elevation of cardiac glucose metabolism may be one more example of the prominent reversion to fetal gene expression that occurs during CHF (34). Unlike the adult heart, glycolysis is the primary energy source of the fetal heart (35). In the adult heart, glucose and fat metabolism are tightly and inversely regulated, as illustrated by the Randle cycle (27). Impairment of fat uptake or fat metabolism will increase cardiac glucose metabolism, and it has been shown that impaired fat metabolism is detrimental to the heart (2). In a Type 2 diabetic environment (4), increased cardiac glucose uptake improves cardiac function. However, the effect of increased cardiac glucose metabolism has not been tested in healthy animals.

Metabolic flux analysis (17) has demonstrated that the control of cardiac glycolysis is shared by several reactions. One of the control reactions is carried out by 6-phosphofructo-1-kinase (PFK-1) (12, 29), which catalyzes the phosphorylation of fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (Fru-1,6-P2). F6P is in equilibrium with glucose-6-phosphate (G6P), and these two sugars initiate glycogen synthesis, the hexosamine pathway, and the hexose monophosphate shunt. Thus, PFK-1 not only has an important role in regulating glycolysis but, by controlling the metabolism of F6P, PFK-1 can also modulate several important reactions branching off of glycolysis. PFK-1 activity is tightly controlled and negatively regulated by products of fat metabolism, including ATP and citrate. The most important positive regulator of PFK-1 is fructose-2,6-bisphosphate (Fru-2,6-P2). The bifunctional enzyme PFK-2 controls levels of F-2,6-P2 by catalyzing two opposing reactions: F6P + ATP → Fru-2,6-P2 + ADP and Fru-2,6-P2 + Pi → F6P + P. The development of the kinase-active/phosphatase-deficient PFK-2 mu-
H2890  INCREASED CARDIAC PHOSPHOFRUCTOKINASE

Cardiac-specific expression was obtained by ligating a 1.6-kb KpnI/HindIII fragment of kinase-active liver PFK-2 (38, 39) behind the α-myosin heavy chain (MHC) promoter (10). The transgene was designated Mk (for the MHC promoter and the kinase-active PFK-2 gene). Transgenic mice were produced on a FVB background and maintained as heterozygotes by breeding to FVB mice. Standard embryo microinjection procedures were used for producing transgenic animals. All procedures conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996) and were approved by the United State Department of Agriculture-certified institutional animal care committee. Male mice aged 90–130 days were used in the following experiments.

**Measurement of metabolites.** For the assays of G6P, F6P, and Fru-1,6-P2, hearts were homogenized in 1 M ice-cold perchloric acid (5). The supernatant from neutralized tissue extracts was used for the estimation of these metabolites by the fluorometric method (23).

Cardiac Fru-2,6-P2 was extracted from fresh heart tissue in 10–20 volumes of 50 mM NaOH and kept at 90°C for 5 min. The extract was cooled and neutralized at 0°C by the addition of ice-cold 1 M acetic acid in the presence of 20 mM HEPES. After centrifugation at 8,000 g for 10 min, the supernatant was collected and assayed for Fru-2,6-P2 by the PFK-1 activation method (36).

For the assay of glycogen, snap-frozen tissue was weighed, homogenized in 9 volumes of 30% KOH at 0°C, and then heated at 70°C for 30 min. Glycogen was precipitated with absolute alcohol and saturated sodium sulfate and redissolved in 0.1 M acetate buffer (pH 4.7). Homogenate glycogen (10 μl) was then hydrolyzed by glucose by the addition of 50 ng amyloglucosidase (Boehringer-Mannheim) in 100 μl of 0.1 M acetate buffer. Glucose was then measured by a fluorometric assay using hexokinase and G6P dehydrogenase as previously reported (22).

**Cardiac perfusion for measurements of glycolysis, palmitate oxidation, and lactate production.** Langendorff perfusions were carried out as previously described (21, 22). The heart was rapidly cannulated through the aorta and retrogradely perfused at 2 ml/min with Krebs-Henseleit (KH) buffer, which consisted of 120 mM NaCl, 20 mM NaHCO3, 4.6 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgCl2, 1.25 mM CaCl2, and 5 mM glucose. Throughout the perfusion, KH buffer was continuously equilibrated with 95% O2–5% CO2, which maintained pH of 7.4, and temperature was maintained at 37°C. The heart was paced throughout the procedure at 6 Hz (6 V, 3 ms). Perfusion pressure and contractility were monitored continuously during the perfusion, as previously described (21, 22). To study the effect of insulin, baseline glycolysis was determined for the first 30 min followed by 50 min in the presence of 200 μU/ml insulin. Glycolysis in the presence of palmitate was measured by bringing the perfusate to 0.4 mM palmitate (5) by the addition of 1/20th volume of 8 mM palmitate bound to 10% BSA in KH buffer.

Lactate production and glycolysis measurements with [5-3H]glucose were performed with perfusion buffer containing 5 mM glucose as previously described (8). Palmitate oxidation was measured by perfusion with 5 mM glucose plus 0.4 mM palmitate containing 0.75 μCi/ml [9, 10-3H] palmitate. Tritiated water produced from tritiated palmitate (5) by the addition of 1/20th volume of 8 mM palmitate was measured by bringing the perfusate to 0.4 mM palmitate (5) by the addition of 1/20th volume of 8 mM palmitate bound to 10% BSA in KH buffer.

**Histological experiments.** Collagen accumulation in heart sections was determined as previously described (1). Heart sections (5 μm) were placed on slides, deparaffinized, and incubated with a saturated solution of picric acid containing 0.1% Sirius red for staining collagen and 0.1% fast green, which stains noncollagen proteins. Sections were kept in the dark and incubated for 30 min. Sections were rinsed with distilled water, dehydrated, and then mounted with permount. Sections were visualized and photographed, and the interstitial fibrosis was quantified by a blinded observer using a scale of 0–2 based on the severity of the collagen accumulation, as previously described (8).

**Cardiomyocyte assay.** Cardiomyocytes were isolated, and myocyte contractility was measured as previously described (41). For the oxygenated assay, myocytes were placed in an open chamber at 22°C in HEPES-buffered KH buffer [135 mM NaCl, 4 mM KCl, 1 mM MgCl2, 10 mM HEPES, 0.33 mM NaH2PO4, 10 mM glucose, 10 mM 2,3-butanediol monoxime (BDM), and 1.2 mM CaCl2; pH 7.4] for 2 h. BDM was included in the contractility assay buffer because it preserves rod-shaped myocytes during metabolic inhibition (18). We (40) have previously described the use of BDM during hypoxic assays of myocyte contractility. For hypoxia, cardiomyocytes were perfused in the same buffer saturated with N2 for 15 min and maintained and assayed in a sealed chamber for 2 h at 22°C. Myocytes were stimulated at 1 Hz using platinum electrodes attached to the chamber. The mechanical properties of ventricular myocytes were assessed using a video-based edge detection system (IonOptix, Milton, MA) as previously described (41). Cell shortening and relengthening were assessed using the following indexes: peak shortening, time to 90% relengthening, and maximal velocities of shortening and relengthening (+dLV/dt).

**PKF-2 expression analysis.** PFK-2 protein was analyzed by Western blot analysis as previously reported (8). In brief, PFK-2 was extracted from fresh hearts by homogenization, and the PFK-2 enzyme was precipitated with 40% PEG. Pellets were resuspended, and the concentration of extracted protein was measured by the BCA method (Pierce Chemical, Rockford, IL). Equal amounts of extracted protein (100 μg) were used for Western blots. Rabbit anti-rat liver PFK-2 serum was used as the primary antibody at a 1:1,000 dilution.
RESULTS

**Transgenic lines.** Transgenic mice were generated with the transgene Mk, which contained a kinase-active/bisphosphatase-deficient mutant of liver PFK-2 (37) regulated by the cardiосpecific α-MHC promoter (10). Six lines of Mk transgenic mice were generated on a FVB background and were designated as lines Mk1 to Mk6. The founders of lines 1, 2, 4, and 5 produced litters. Western blots with antibody made against liver PFK-2 (Fig. 1A) demonstrated obvious overexpression of the transgene in Mk mouse hearts. To confirm the increase in PFK-2 activity, we measured the level of Fru-2,6-P2 in transgenic and control hearts. Cardiac Fru-2,6-P2 was elevated by three- to fourfold in all transgenic lines (Fig. 1B). Mk1 and Mk2 mice were produced first and had indistinguishable phenotypes for gene expression and Fru-2,6-P2 levels, and they were used interchangeably in experiments concerning phenotype.

**Cardiac metabolite concentrations.** By modifying PFK activity, the Mk transgene is expected to alter the concentration of metabolites of the glycolytic pathway. Levels of several metabolites were measured in flash-frozen hearts from FVB and Mk transgenic mice that had been fasted for 3 h. Table 1 shows these results. G6P was reduced by ~1.6 fold in Mk transgenic hearts. Coincident with the reduction in G6P levels, glycogen was decreased by more than eightfold in Mk hearts. Two metabolites downstream of PFK, Fru-1,6-P2 and pyruvate, were increased in concentration; however, the increase did not reach statistical significance. Fru-1,6-P2 was measured as the combined pool of Fru-1,6-P2, dihydroxyacetone phosphate, and glyceraldehyde-3-phosphate since these metabolites are in equilibrium and are most accurately measured together (23).

**Effect of kinase-active PFK-2 on cardiac metabolism.** The effect of the Mk transgene on glycolysis was assessed in Langendorff-perfused hearts by measuring the metabolism of 5-tritiated glucose. The release of tritiated water measures the glycolytic steps through the triose phosphate isomerase reaction. The amount of lactate produced during the perfusion was also measured. As shown in Fig. 2, in both the presence and absence of palmitate, the release of tritiated water and lactate were significantly elevated in Mk transgenic hearts compared with control hearts. The Mk effect on glycolysis was evident both before and after the addition of insulin. The increase in glycolysis did not appear to be related to contractility or perfusion pressure since no significant differences were observed for contractility between transgenic and control hearts at any time point (data not shown). Also, in both groups, the perfusion pressure averaged 65 mmHg while the flow rate was maintained at 2 ml/min.

To determine if the transgene altered the effect of palmitate and insulin, the results for tritiated water release were replotted

---

Table 1. Concentrations of glycolytic intermediates in FVB and Mk hearts

<table>
<thead>
<tr>
<th></th>
<th>Glucose-6-Phosphate, nmol/g</th>
<th>Fructose-1,6-Bisphosphate, nmol/g</th>
<th>Fructose-2,6-Bisphosphate, nmol/g</th>
<th>Pyruvate, nmol/g</th>
<th>Glycogen, μmol/g</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVB</td>
<td>225±67</td>
<td>277±93</td>
<td>5.12±0.88</td>
<td>133±44</td>
<td>2.4±1.94</td>
</tr>
<tr>
<td>Mk</td>
<td>140±17</td>
<td>356±108</td>
<td>10.4±1.34</td>
<td>227±110</td>
<td>0.27±0.22</td>
</tr>
<tr>
<td><em>P value</em></td>
<td>0.01</td>
<td>0.25</td>
<td>0.01</td>
<td>0.15</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Values are means ± SE for at least 5 mice/group after a 3-h fast. *P* values were determined by Student's *t*-test.

AJP-Heart Circ Physiol • VOL 294 • JUNE 2008 • www.ajpheart.org
in Fig. 3. Before the addition of insulin, we found palmitate to be a more potent inhibitor of glycolysis in FVB mice (55% inhibition) than in Mk mice (18% inhibition). In the presence of insulin, palmitate did not reduce glycolysis in FVB or Mk hearts.

Our laboratory (8) has previously reported that a transgene that reduced cardiac Fru-2,6-P2 blunted the insulin response in perfused hearts. However, the present study (Fig. 3, C and D) failed to support the converse: compared with FVB hearts, there was no increase in the insulin response in Mk hearts with

![Figure 2](http://ajpheart.physiology.org/)

**Fig. 2.** The kinase-active PFK-2 transgene increases glycolysis in Langendorff-perfused hearts. A and C: glycolysis (A) and lactate release (C) without palmitate. B and D: glycolysis (B) and lactate release (D) in the presence of 0.4 mM palmitate. The shaded box shows the addition of 200 µU/ml insulin. Values for FVB and Mk hearts were compared by two-way ANOVA (*P < 0.05). Values are means ± SE for at least 5 mice/time point.

![Figure 3](http://ajpheart.physiology.org/)

**Fig. 3.** Effect of palmitate and insulin (Ins) on glycolysis in FVB mice and Mk mice. Preinsulin glycolysis was reduced by 55% (*P < 0.02) in FVB mice (A) but only by 18% in Mk mice (B; P = 0.24). In the presence of insulin, palmitate did not reduce glycolysis in FVB or Mk hearts. C and D: insulin elevated glycolysis in FVB (C) and Mk (D) hearts with or without palmitate (#P < 0.02, preinsulin vs. insulin by paired t-test). The relative effect of insulin was greater in the presence of palmitate because insulin decreased palmitate inhibition of glycolysis. Data are from Fig. 2 at 30 and 80 min.
increased Fru-2,6-P$_2$. In the absence of palmitate, insulin increased glycolysis by 39% and 31%, respectively, in FVB and Mk hearts. In the presence of palmitate, the insulin response was markedly increased, by 230% of basal in FVB mice and by 93% of basal in Mk hearts. The very large insulin response in palmitate-perfused FVB hearts was due primarily to the potent inhibition of basal glycolysis by palmitate (Fig. 3A), which was eliminated by the addition of insulin. Folmes et al. (9) have also reported that insulin has a greater effect on glycolysis in the presence of palmitate.

In addition to the Mk-induced increase in glycolysis, we found a 30–50% significant reduction in palmitate oxidation in Mk hearts that was true throughout the duration of the perfusion (Fig. 4A). Insulin produced a significant reduction ($P < 0.01$ by paired $t$-test) in palmitate oxidation in both FVB and Mk hearts. The average decrease produced by insulin was 32 ± 1% and 42 ± 6% for FVB and Mk hearts, respectively (Fig. 4B), which was not significantly different in the two types of hearts (FVB vs. Mk, $P = 0.13$).

**Myocyte contractility in hypoxia.** To determine the effect of increased glycolysis on cardiomyocyte contractility and the response to hypoxia in Mk transgenic hearts, myocytes were isolated from Mk and FVB hearts and incubated with oxygenated or nitrogen-bubbled Krebs buffer. Myocyte contractility was measured using a video-based edge detection system, and the results are shown in Fig. 5. Under normoxic conditions, there were no significant differences in contractility between Mk and FVB myocytes, as assessed by $±dL/dt$ and the percentage of peak shortening. However, under hypoxic condition, Mk myocytes showed significantly increased contractility compared with FVB control myocytes for all three parameters.

In FVB myocytes, hypoxia reduced all of the parameters of contractility by 20% to >30%, but in Mk myocytes, hypoxia had a 0–10% effect. These results indicate that the Mk transgene provided almost complete protection from hypoxia-induced contractile deficits in our culture conditions.

**Myocardial infarct size.** To establish whether the cytoprotective effects associated with Mk transgenesis in isolated myocytes extended to the in vivo setting, we subjected FVB and Mk mice to experimental myocardial infarction. As shown in Fig. 6, the AARs for infarction with respect to left ventricular (LV) size were not significantly different between FVB (46.3 ± 3.3%) and Mk (49.3 ± 6.3%) groups. Infarct sizes expressed relative to the AAR were also not different between FVB (28.7 ± 5.1%) and Mk (26.2 ± 4.8%) group. Likewise, infarct sizes expressed relative to the entire LV were not different between FVB (13.5 ± 2.8%) and Mk (12.8 ± 2.8%) groups.

**Cardiac hypertrophy in transgenic hearts.** Despite the fact that the Mk transgene was beneficial to hypoxic cardiomyocyte function, we noted an increase in cardiac size. When measured, we found that the heart weight and heart weight-to-body weight ratio were significantly increased by −17% compared with FVB control mice, whereas body weights were similar between Mk mice and FVB mice (Table 2). To determine if this corresponded to a change in cardiomyocyte size, we also compared isolated cardiomyocyte length (Table 2) using video-based edge detection. Cardiomyocyte length in Mk transgenic hearts was significantly longer than that in FVB hearts. The cardiac hypertrophy raised the possibility that elevated glycolysis was detrimental to the heart. The expression of two markers of cardiac stress, β-MHC and BNP, were unchanged (Fig. 7), and hematoxylin and eosin staining (Fig. 8A) of Mk hearts appeared normal. However, Sirius red staining for fibrosis appeared to be consistently increased in Mk hearts (Fig. 8A), and this was confirmed by semiquantitative analysis (Fig. 8B).

**DISCUSSION**

Lipid metabolism provides most energy for cardiac contraction, but under some pathological conditions, such as hypertrophy and ischemia-reperfusion (1), glucose metabolism increases. It is not clear whether this increase in glucose metabolism is a beneficial, adaptive response of the heart or a detrimental, maladaptive response. To test this, we developed transgenic mice designed to have a specific and permanent increase in cardiac glycolysis independent of hypertrophy or ischemia. Multiple lines of mice were produced with a cardiac-specific, bisphosphatase-deficient mutant of the enzyme PFK-2, designated transgene Mk. The transgene produced a three- to fourfold increase in cardiac levels of Fru-2,6-P$_2$, which is a potent stimulator of the glycolytic regulatory enzyme PFK-1. In the present study, we show multiple effects of the transgene. It increased glycolysis, reduced palmitate oxidation, and made glycolysis less susceptible to inhibition by palmitate. The transgene markedly improved myocyte contractility during...
hypoxia, but it did not alter the infarct size in response to ischemia in vivo. Despite some beneficial actions, the Mk transgene promoted hypertrophy and cardiac fibrosis.

For the effects produced by the Mk transgene to provide relevant information about the role of Fru-2,6-P2 in cardiac pathology, it is important that the increase in Fru-2,6-P2 concentration in Mk transgenic hearts be similar to the concentrations achieved in known conditions of cardiac pathology. Pressure overload hypertrophy induces a two- to sixfold increase in Fru-2,6-P2 (3, 26). Anoxia or ischemia results in a two- to threefold elevation in cardiac Fru-2,6-P2 content (25). And stimulation of isolated cardiomyocytes with insulin produces a fourfold increase in Fru-2,6-P2 content (20). Thus, the three- to fourfold increase in Fru-2,6-P2 seen in our transgenic mice is similar to the increases produced by insulin, hypertrophy, and anoxia or ischemia in the heart (3, 20, 25, 26).

An elevation in Fru-2,6-P2 levels should stimulate activity of PFK-1. If this is true, glycolytic metabolites upstream of PFK-1 should be reduced and metabolites downstream of PFK-1 should be increased in transgenic hearts. Our data showed that the concentration of G6P was significantly reduced by 1.6-fold. This reduction was likely the result of increased disposal of Fru-6-P by greater flux through PFK-1, creating a drain on G6P concentrations. Glycogen, the production of which branches off upstream of PFK-1, was diminished by almost ninefold in transgenic hearts. The large magnitude of the glycogen effect may be due to the fact that G6P has two roles in the control of glycogen content: G6P is a substrate for glycogen production and G6P is a positive regulator of glycogen synthase (30). In addition, the increased PFK-1 activity promotes greater use of glycogen to fuel glycolysis. The expected increase in metabolites downstream of PFK-1 was not as clear as the decrease in upstream metabolites. The concentrations of Fru-1,6-P2 and pyruvate increased 50–70%, but the changes were not statistically significant. This smaller downstream effect may reflect cardiac adaptation to increased PFK-1 flux. This could be due to greater lactate disposal, as we saw in perfused transgenic hearts, or to greater mitochondrial oxidation of pyruvate obtained from glucose (15–18).

Table 2. Mk hearts and myocytes are enlarged

<table>
<thead>
<tr>
<th></th>
<th>Age, days</th>
<th>Body weight, g</th>
<th>Heart Weight, mg</th>
<th>Heart Weight/Body Weight</th>
<th>Myocyte Length, μm</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVB</td>
<td>138±2</td>
<td>29.9±0.6</td>
<td>132.7±3.3</td>
<td>4.44±0.07</td>
<td>126±3</td>
</tr>
<tr>
<td>Mk</td>
<td>131±4</td>
<td>29.8±0.6</td>
<td>155.3±2.5*</td>
<td>5.21±0.08*</td>
<td>151±3*</td>
</tr>
</tbody>
</table>

Values are means ± SE; n = 13 male Mk mice and 27 male FVB mice. Myocyte length was the average of 52 myocytes from 4 mice/group. *P < 0.001 by Student’s t-test.
The conversion of F6P to Fru-1,6-P2 by PFK is one of the rate-limiting, regulated steps of cardiac glycolysis. Therefore, we anticipated an increase of glycolytic flux in perfused Mk hearts. Even in the absence of lipid, glycolytic flux in Langendorff-perfused Mk hearts was consistently 20% higher than in nontransgenic hearts. This was not secondary to elevated contractility or to altered coronary vascular resistance since we detected no effect of the transgene on these parameters. The most likely cause was the increased activity of PFK. These results support a significant role for Fru-2,6-P2 even in the absence of lipid. The addition of 0.4 mM palmitate to the perfusate produced an apparent twofold increase in the impact of the transgene on glycolytic flux. This was because palmitate depressed glycolysis less in Mk hearts than in FVB control hearts. Fatty acids inhibit glycolysis in large part by inhibiting PFK via the PFK inhibitors citrate and ATP. Fru-2,6-P2 antagonizes this inhibition (12). In addition, we found that palmitate oxidation was about twofold lower in Mk hearts; consequently, palmitate perfusion produced less citrate and ATP in Mk hearts than in FVB hearts. Therefore, we suggest that a combination of elevated Fru-2,6-P2 and reduced production of citrate and ATP minimized the effect of fatty acids to inhibit glycolysis in Mk hearts. The mechanism behind the Fru-2,6-P2-reduced palmitate oxidation is less clear. In previous studies, upregulation of glycolysis with a glucose transporter (Glut)1 transgene increased fatty acid oxidation (24), whereas upregulation of glycolysis with a Glut4 transgene had no effect on fatty acid oxidation (5). It is also possible that Fru-2,6-P2 may have unrecognized direct or indirect effects on lipid metabolism.

In our previous transgenic model with reduced cardiac levels of Fru-2,6-P2, sensitivity to insulin was sharply reduced (8). This led us to expect an increase in cardiac insulin sensitivity in our new Mk model. However, this was not the case for several parameters of insulin action including stimulation of glycolysis, inhibition of palmitate oxidation, and phosphorylation of Akt (data not shown). Our previous (8) and present results suggest that a basal level of Fru-2,6-P2 is required for a normal insulin response but that further elevation of Fru-2,6-P2 beyond normal levels does not produce a further increase in insulin sensitivity.

Basal contractility was unchanged in Mk hearts when assayed either during Langendorff perfusion or in isolated cardiomyocytes. This is consistent with results we have obtained with two other transgenic models of increased or decreased glycolysis (8, 22). The results from all of these transgenic lines show that altering glycolysis for many months does not change myocyte contractility when assayed in oxygenated conditions. During hypoxia, glycolysis becomes more important to myocyte function. Consistent with this, cultured Mk myocytes were much less susceptible to hypoxia. In fact, under hypoxic conditions that significantly impaired control myocytes in our assays, we saw no detectable decline in Mk cardiomyocyte contractility. Resistance to hypoxia is the opposite of what we previously found in myocytes with impaired glycolytic capacity (8). This confirms the essential role of glycolysis during hypoxic conditions. However, isolated myocyte experiments do not allow for extrapolation to in vivo conditions. In vivo, multiple fuel substrates are available, in contrast to the sole substrate of glucose used for in vitro myocyte culture. Also, excess lactate from increased glycolysis in Mk hearts may
accumulate in poorly perfused myocardium of ischemic intact hearts (33). In addition, fibrosis and hypertrophy in Mk mice could increase cardiac work during in vivo ischemia, and the reduced glycogen content (Table 1) of Mk hearts reduced carbohydrate reserves. Therefore, it was not a complete surprise that the protection from hypoxia in isolated myocytes was not replicated in vivo, where infarct damage following ischemia-reperfusion was similar in transgenic and control hearts. A more complete analysis of ischemia resistance in Mk hearts should be undertaken using low-flow and stop-flow perfusion of isolated hearts to distinguish what components contribute to resistance to hypoxia of cardiomyocytes in culture but not in vivo.

Heart weight, heart weight-to-body weight ratio, and cardiomyocyte length were all significantly elevated in Mk transgenic mice, demonstrating hypertrophy. To test if this mild hypertrophy indicated cardiac pathology, we examined two other signs of pathology: upregulation of “fetal state cardiac genes” (29 –30) and induction of fibrosis. There was no significant effect of the Mk transgene on the expression of β-MHC and BNP. Since these genes are upregulated by stress, this did not support the conclusion that Mk hearts were undergoing severe pathological stress (32). On the other hand, we found that cardiac fibrosis was increased, and fibrosis is a cardiac stress marker (6). Overall, the weight of the evidence, fibrosis and hypertrophy imply that the Mk transgene induces a mild state of pathology. By constitutively elevating Fru-2,6-P₂, the Mk transgene chronically elevated glycolysis and blocked the normal mechanisms controlling carbohydrate usage. The increased glycolysis of chronic heart failure may ultimately be maladaptive. It is striking that our present transgene, which increased Fru-2,6-P₂, both produced mild hypertrophy and fibrosis. This demonstrates the sensitivity of the heart to disruption of normal metabolic control.

In summary, we produced mice with chronic and stable elevation of cardiac Fru-2,6-P₂. This resulted in significant changes in cardiac metabolic concentrations, increased glycolysis, reduced palmitate oxidation, and protection of isolated myocytes from hypoxia. Finally, chronic elevation of glycolysis produced detrimental effects, suggesting that the elevation of glycolysis in failing hearts could be injurious to an already compromised heart.

GRANTS

This work was supported by National Institutes of Health Grants HL-62892 and DK-073586 (to P. N. Epstein) and HL-8320 (to S. P. Jones) and by American Heart Association National Scientist Development Grant 055270N (to S. P. Jones).

REFERENCES


H2896 INCREASED CARDIAC PHOSPHOFRUCTOKINASE


